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Introduction
Dopamine (DA) plays a key signaling role in the nucleus accumbens (NAc) to control reward (Ikemoto and Panksepp, 1999; Di Chiara, 2002) . Incoming glutamatergic and cholinergic inputs have also been shown to control information processing in the NAc (Kalivas, 2009; Mark et al., 2011) . Since both ionotropic glutamate receptors, namely Nmethyl-D-aspartate receptors (NMDAR), as well as nicotinic acetylcholine receptors (nAChR) can control the release of DA through a direct presynaptic action in DAergic terminals (Pittaluga et al., 2001) , the understanding of this presynaptic neuromodulation is essential to understand the glutamatergic and cholinergic regulation of reward processes.
It is particularly important to consider the glutamatergic and cholinergic neuromodulation system simultaneously since there is evidence for a tight interplay between both receptor systems. In fact, the functional impact of nicotine is dependent on ionotropic glutamatergic receptors (Liechti and Markou, 2008; Reissner and Kalivas, 2010; D'Souza and Markou, 2011; Timofeeva and Levin, 2011) . Conversely, the acute nicotine administration alters the functional responses of ionotropic glutamate receptors in different brain areas (Risso et al., 2004a; Yamazaki et al., 2006; Vieyra-Reyes et al., 2008 , Lin et al., 2010 and chronic nicotine administration affects NMDAR subunit composition (Delibas et al., 2005; Levin et al., 2005; Wang et al., 2007; Rezvani et al., 2008; Kenny et al., 2009) . Importantly, previous studies have provided initial evidence that nAChR and NMDAR might also interact to control the release of DA in the NAc (Risso et al., 2004a) , whereby the co-activation of nAChR with NMDAR provides a sufficient membrane depolarization to engage NMDAR (Desce et al., 1992; Raiteri et al., 1992; Pittaluga et al., 2005; Tebano et al., 2005) . In contrast, the chronic exposure to nicotine was shown to differently modify the ability of ionotropic glutamate receptors to trigger the release of biogenic amines in different brain regions (Risso et al., 2004b; Grilli et al., 2009b) . Notably, this effect involved the control of AMPAR trafficking M A N U S C R I P T
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For the release experiments, NAc synaptosomes were incubated for 20 min at 37°C with consecutive 3-min fractions (b1-b4) were collected. The synaptosomes were then exposed to agonists or to depolarizing agent (4-aminopyridine) at t = 39 min, until the end of superfusion, while antagonists were present from 8 min before agonists. When carrying out a pre-treatment with nicotine, the synaptosomes were exposed for 10 min to nicotine (30 µM) or to nAChR agonists at t =29 min of superfusion in the absence or in the presence of nAChR antagonists.
The effluent samples collected and the trapped synaptosomes were then counted for radioactivity. Agonist-induced effects were expressed as the percentage of the total retained radioactivity, and were calculated by subtracting the neurotransmitter content released in the four fractions collected under basal condition (no drug added) from that released in presence of the stimulus.
Calcium imaging in individual nerve terminals
Purified nerve terminals with less than 2% of postsynaptic or glial contaminations (Rodrigues et al., 2005a ) were prepared as previously described using a discontinuous Percoll gradient (Dunkley et al., 1986) . The calcium imaging of individual nerve terminals was carried out as previously described (Rodrigues et al., 2005b (Lev-Ram et al., 1992; Castro et al., 1995; Mateo et al., 1998) . The basal ratio was measured for 60 sec (equivalent to 12 cycles at the 2 emission wavelengths) before superfusion for 60 sec with NMDA (100 µM) + glycine (10 µM). To test the impact of the pretreatment with different nAChR agonists and antagonists, nicotine (100 µM), 5IA85380 (10 nM) or DHβE (1 µM) were added 1 min before exposure to NMDA + glycine. A 30 s pulse of KCl (final concentration of 25 mM) was applied at the end of each experiment to confirm the preservation of the viability of the studied nerve terminals. All the tested compounds were prepared in normal HBM medium, or without Mg 2+ to study the NMDA effect, and were added to the superfused nerve terminals using a rapid-pressurization system (AutoMate Scientific, Berkeley, CA, USA) in 95% O 2 and 5% CO 2 .
Immunocytochemical assays
The immunocytochemical identification of presynaptic receptors in different types of
nerve terminals was carried out essentially as described previously (Rodrigues et al., 2005a,b) . Briefly, purified nerve terminals (500 µg of protein) were resuspended in 1 mL of phosphate-buffered saline (PBS containing, in mM: 137 NaCl, 2.6 KCl, 1.5 KH 2 PO 4 , 8.1
Na 2 HPO 4 , pH 7.4) and adsorbed onto poly-D-lysine-coated cover slips, although in some cases, the immunocytochemical detection was carried out after the analysis of calcium levels in individual nerve terminals described above and, in such cases, we used gridded cover slips for unambiguous identification of each individual nerve terminal. After fixation with 4%
(w/v) paraformaldehyde for 15 min followed by washing twice with PBS, the nerve terminals were permeabilized in PBS with 0.2% Triton X-100 for 10 min, blocked for 1 h in PBS with 3% BSA and 5% normal horse serum and washed twice with PBS. Triplicate coverslips from each sample were incubated at 25 °C for 1 h and the following primary antibodies were diluted in PBS with 3% BSA and 5% normal horse serum: rabbit anti-synaptophysin (1:200), mouse anti-NR1 (1:500), rat anti-DAT (1:1000), rabbit anti-α4 nAChR (1:500). After three washes with PBS with 3% BSA and 3% normal horse serum, the nerve terminals were with another in pattern recognition (Gonzalez and Wintz, 1987 
Biotinylation and immunoblot assay
The cell surface levels of the NR2B subunit were evaluated by performing surface biotinylation of synaptosomes from the NAc and subsequent immunoblot analysis (Jayanthi et al., 2004; Johnson et al., 2005) . Briefly, crude NAc synaptosomes were prepared from 2 rats, re-suspended in HBM medium at 4°C, divided into 2 aliquots (500 µg protein each) and were incubated for 10 min at 37 °C with mild shacking; then one aliquot was treated for 10 min with 30 µM nicotine (T) while the other one was kept as control (C). The reaction was stopped with a cold (4 ºC) washing buffer composed by (mM): 150 NaCl, 1 EDTA, 0.2% BSA, 20 Tris, pH 8.6. The synaptosomes were then washed twice in ice-cold washing buffer and labeled with 2 mg/mL of sulfo-NHS-SS-biotin in PBS/Ca-Mg of the following composition (mM): 138 NaCl, 2.7 KCl, 1.8 KH 2 PO 4 , 10 Na 2 HPO 4 , 1.5 MgCl 2 , 0.2 CaCl 2 , pH 7.4 for 1 h at 4 °C. The biotinylation reaction was stopped by incubating the biotinylated
synaptosomes with 1 M NH 4 Cl for 15 min at 4 °C, followed by two washes with ice cold PBS/Ca-Mg with 100 mM NH 4 Cl to quench biotin. Biotinylated synaptosomes were then lysed in a RIPA buffer (500 µL) (10 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate, 1 mM orthovanadate, containing protease inhibitors). This lysate was centrifuged at 20,000 × g for 10 min at 4 °C, and samples (100 µg) were incubated with streptavidin magnetic beads (40 µL) for 1 h at room temperature under shaking. Streptavidin magnetic beads were added to the biotinylated synaptosomes (nicotine treated, T, and nicotine untreated, C, synaptosomes) to pull down the biotinylated proteins, as well as to the non-biotinylated synaptosomes to evaluate the specificity of streptavidin pull-down (B). After extensive washes, 1x SDS-PAGE buffer was added and samples were boiled for 5 min at 95 °C before loading on 10% SDS-PAGE gels and then transferred onto PVDF membranes. Non-specific binding sites were blocked with Tween containing Tris-buffered saline (t-TBS, with 20 mM Tris, 150 mM NaCl, and 0.1% Tween 20, containing 5% non-fat dried milk) for 1 h at room temperature and the protein of interest were detected using the primary antibodies, rabbit anti-NR2B (1:2,000) or mouse anti-actin
(1:10,000). After washing, the membranes were incubated for 1 h at room temperature with the appropriate horseradish peroxidase-linked secondary antibody (1:20,000), and the immunoblots were visualized with an ECL (enhanced chemiluminescence) Plus Western blotting detection system. The immunoreactivity of NR2B subunits was monitored in the total synaptosomes (Syn), in control and nicotine pretreated biotinylated synaptosomes (respectively C and T) and in the streptavidin pull-down of the non-biotinylated synaptosomal lysate (B). GluA2 and β-actin bands from sub-fractionated samples as well as GluA2 bands from biotinylation experiments were quantified by using the ImageJ 1.46b software. The intensity of the protein bands was within linear range of the standard curves that were obtained by loading increasing amounts of samples.
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Data analysis
Statistical comparison of the results was carried out using a Student's t-test for independent means (for single pairs comparison) while multiple comparisons were performed with one-or two-way ANOVA followed by Tukey-Kramer post-hoc test. Values are expressed as mean±S.E.M and were considered significant for p < 0.05. 
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Results
NMDARs are located in dopaminergic terminals of the NAc
In order to determine the existence and estimate the percentage of DA nerve endings equipped with NMDARs, synaptosomes were labeled with antibodies against synaptophysin, a generic marker of presynaptic terminals, DAT, a marker of DA nerve endings, and GluN1 subunits (Fig.1a) . The histogram displayed in Fig.1b shows that the 40% of the synaptophysin-positive nerve terminals were also labeled with the anti-GluN1 subunit antibody and with anti-DAT antibody; furthermore, around 20% of dopaminergic nerve terminals were GluN1-immunopositive and 20% of GLuN1-immunopositive terminals were dopaminergic (Fig 1b) , thus confirming the co-localization of GluN1 subunits and DAT proteins on a subset of NAc nerve terminals.
NMDARs trigger DA outflow from nerve terminals in a manner controlled by nAChR
We then tested the functional impact of NMDA on the release of (Fig. 1c) ; this reduction of NMDAinduced DA release was completely counteracted when the synaptosomes were pretreated with nicotine (30 µM) plus mecamylamine (20 µM) (Fig. 1c) . It is worth noting that we already observed a significant inhibitory effect of the NMDA-evoked [ 3 H]DA overflow after pretreatment with nicotine at very low concentrations, similar to these (15 ng/mL) present in M A N U S C R I P T
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12 the blood of smokers ( This interaction between nAChRs and NMDARs was further confirmed by measuring the evoked elevation of intracellular calcium levels in individual NAc synaptosomes. As shown in Fig. 1d , both NMDA (100 µM) and nicotine (100 µM) triggered an enhancement of intracellular calcium in individual NAc synaptosomes; furthermore, the response to NMDA (100 µM) was curtailed by the previous exposure to nicotine (100 µM) (see also Fig. 1e ).
Pharmacological characterization of nAChR and NMDAR in dopaminergic terminals
Fig 2a shows the stimulatory effects of several nAChR agonists on [ 3 H]DA release. The selective α4β2-containing nAChR agonist 5IA85380 (10 nM) produced a stimulatory effect similar to that produced by nicotine, whereas the partial agonist, varenicline (10 µM), also produced a stimulatory effect with an amplitude lower than that of nicotine. Cotinine, the major metabolite of nicotine, even at an high concentration (30 µM), was inefficacious to elicit [ 3 H]DA release. Choline, an α7-containing nAChR agonist when used at high concentration (1 mM), caused a modest stimulatory effect suggesting that, at this concentration, it may be partially effective also on other nAChRs (Fig. 2a) .
We next used an immunocytochemical approach to directly confirm the presence of nAChR 4 subunits in NAc dopaminergic terminals. We found that near 40% of synaptosomes (synaptophysin-positive) were labeled with the anti-α4 nAChR subunit and with anti-DAT antibodies (Fig. 2b,c) . The average data displayed in the histogram of Fig. 2c shows that 30% of the dopaminergic terminals (DAT-positive) were α4-immunopositive and near 30% of the α4-positive terminals were dopaminergic (Fig. 2c) .
The pharmacological characterization of the NMDARs stimulating DA release from NAc synaptosomes is presented in Fig. 3 . The NMDA (100 µM)-evoked DA release was almost completely antagonized in presence of MK801 (1 µM) and partially inhibited by CGS-M A N U S C R I P T
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13 ifenprodil (1 µM), inhibited the NMDA (100 µM)-evoked DA release, whereas two GluN2A-preferring antagonists, CPP-19755 (1 µM) and ZnCl 2 (1 nM), were devoid of effects (Fig. 3) . Figure 4a shows that only the pre-treatment with 5IA85380 (10 nM), but neither with varenicline (30 µM), cotinine (30 µM) or choline (1 mM), caused a significant reduction of the NMDA (100 µM)-evoked overflow of DA. This ability of the selective α4β2-containing nAChR agonist to decrease NMDAR responses was next confirmed at the single synaptosomal level by following Ca 2+ levels in individual NAc synaptosomes. As shown in Fig. 4b ,c, the NMDA (100 µM)-induced elevation of intracellular calcium levels were reduced by the previous exposure to 5IA85380 (10 nM), an effect which was blunted by the pre-exposure to 5IA85380 (10 nM) together with the selective α4 containing nAChR antagonist DHβE (1 µM) (Fig. 4d,e) . All together, these data indicate that the nAChR-induce modification of the NMDA-induced DA release involves α4-containing nAChRs.
Co-localization and pharmacological characterization of the nAChR controlling NMDAR in dopaminergic terminals
To additionally confirm this contention, we analyzed the calcium levels in NAc terminals and then subsequently tested by immunocytochemistry if they were GluN1-and α4-immunopositive. Indeed, as shown in Fig. 5 , we could identify individual nerve terminals (terminal 1) that are dopaminergic (DAT-positive) and contain both GluN1 and α4 subunits (Fig. 5b, c) , where the pre-treatment with 5IA85380 (10 nM) attenuated the NMDA (100 µM)-induced elevation of intracellular calcium levels (NMDA enhanced [Ca2+]i by 33±2%, n=3 and NMDA+5IA85380 by 17±1%, n=3; p<0.01) (Fig. 5a ). In parallel, we also recorded other terminals (terminal 2) containing both GluN1 and α4 subunits but that were not dopaminergic ( Fig. 5b) , where 5IA85380 (10 nM) failed to modify the NMDA (100 µM)-induced elevation of intracellular calcium levels (NMDA enhanced [Ca2+]i by 33±2%, n=3 M A N U S C R I P T
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14 and NMDA+5IA85380 by 29±3%, n=3) (Fig. 5a ). Finally, there were also nerve terminals responding only to NMDA (terminals 3) or to the 4 nAChR agonist (terminal 4) (Fig 5 a,b) .
nAChR control GluN2B responses in dopaminergic terminals through a control of
GluN2B endocytosis
To further confirm that nAChR pre-treatment selectively affected NR2B-mediated responses in NAc dopaminergic terminals, we tested if nAChR pretreatment still caused any effect in the NMDA-induced DA release from NAc synaptosomes in the presence of the selective NR2B antagonists RO 25-6981. As shown in Fig. 6a , the ability of nicotine (30 µM)
pre-treatment to decrease the NMDA (100 µM)-induced DA release from NAc synaptosomes pre-exposed to nicotine (30 µM) was eliminated in the presence of RO 25-6981 (1 µM) (black bars of Fig. 6a ), indicating that nAChRs only control the NR2B-mediated responses in NAc dopaminergic terminals.
In view of the our previous observations that the control of the response of ionotropic glutamate receptors in nerve terminals might involve a control of their trafficking in and out of the plasma membrane (Grilli et al., 2012) , we posted that nicotine-induced inhibition of NMDA responses in NAc dopaminergic terminals could rely on the internalization of GluN2b receptor subunit. To test this hypothesis, we quantified the surface levels of GluN2B subunit proteins in the plasma membrane of NAc synaptosomes without and after nicotine pretreatment. As shown in Fig. 6b and c, the pretreatment with nicotine (30 µM for 10 min) decreased the density of biotin-tagged GluN2B proteins (Fig. 6b , lane Nic) when compared to control (Fig. 6b , lane Ctr).
Discussion
The present results show that the pre-treatment with nicotine decreases the NMDA- (GluN2a-GluN2d) and/or GluN3 (GluN3a-GluN3b) subunits (Köhr, 2006; Lau and Zukin, 2007; Traynelis et al., 2010) , which dictate NMDAR-mediated functions. By using selective GluN2 antagonists, we here provide evidence that GluN2B subunits are critical members of presynaptic NMDARs located on NAc dopaminergic nerve endings. These GluN2B subunits can undergo phosphorylation and their stoichiometry plays an essential role in the regulation of NMDAR channel properties (Wang and Salter, 1994; Wang et al., 2006; Chen and Roche, 2007; Nakajima, 2012) , leaving open the possibility that the altered NMDA responses might involve either a rearrangement of subunits stoichiometry or a modification of the M A N U S C R I P T
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phosphorylation of NMDARs or alternatively a change in NMDAR trafficking, typified by a reduction of the number of NMDARs present at the plasma membrane level of DA nerve endings. The latter hypothesis is clearly favored since biotinylation studies unveiled a reduced density of GluN2B subunits in NAc synaptosomal plasma membranes following nicotine pretreatment. Furthermore, our previous observation that the acute co-administration of nicotine and NMDA actually enhances NMDAR function (Risso et al., 2004b ) is converted into a negative interaction when the exposure of nicotine is prolonged, is also suggestive of a nAChR-induced control of the trafficking (endocytosis) of NR2B-containing NMDAR after pre-treatment with nicotine.
An additional goal of this study was the pharmacological characterization of the nAChRs responsible for the control of NMDAR-mediated responses in DA terminals of the NAc. It is well known that different nAChR subtypes including αconotoxin MII-sensitive (α6β2β3, α4α6β2β3, α6β2, and α4α6β2) and αconotoxin MII-insensitive (α4β2 and α4α5β2) subtypes mediate nicotine-evoked DA release from striatal synaptosomes (Salminen et al., 2004; Gotti et al., 2007) . Since the inhibitory effect of nicotine pre-treatment was partially counteracted by α-conotoxin MII, it is likely that nAChRs containing the α6 subunit are involved since this subunit is abundant in the NAc (Dwoskin et al., 2008; Papke et al., 2008; Exley et al., 2008a,b) . Importantly, our data using the selective nAChR agonist 5IA85380 indicate that the functional decrease of the NMDAR function is a consequence of the prolonged activation of an α4β2-subtype of nAChRs. This suggests that different nAChRs might fulfill different roles in NAc DA terminals, with α6-containing nAChRs mostly dedicated to directly promoting DA release, whereas α4-containing nAChRs mostly fine-tune other incoming signals such as glutamatergic NMDAR-mediated responses. This selective association of α4β2-containing nAChRs with NMDAR also suggests that these nAChRs might be located extra-synaptically (Lendvai and Vizi, 2008) , since NR2B-containing NMDARs are mainly located extra-M A N U S C R I P T
18 synaptically (Vizi et al., 2013) . Additionally, it is worth noting that α7*-nAChRs do not seem to play a role in NAc DA terminals, as heralded by the absence of effects of choline, and in agreement with the lack of effect of α7-containing nAChR ligands found by others (Salminen et al., 2004 , Gotti et al., 2007 . This contrasts with glutamatergic synapses, where it was found that α7*-nAChRs may enhance the presynaptic surface expression of NMDAR leading to an increased glutamate release during early synaptic development (Lin et al., 2010) .
However, the NMDARs modulating glutamate release are different from those modulating DA release (Pittaluga et al., 2001 ). This suggests that the presynaptic interaction between nAChR and NMDAR can be differently organized in different types of nerve terminals, possibly depending on the different nAChR and NMDAR subtypes involved.
The present findings of a nicotine-induced control of NMDAR responses in NAc DA terminals may be of relevance for the adaptive changes taking place in the brain of smokers.
We previously reported that nicotine, at a concentration achieved by smokers or after nicotine replacement therapy, is able to stimulate DA release in vivo (Millar and Gotti, 2009) . We now found a decrease of NMDAR function upon pre-treatment with a low concentration of nicotine compatible with that achieved by smokers (Fant et al., 1999; Henningfield et al., 2003 ; Table 1 ). It is therefore reasonable to hypothesize that nicotine could cause in vivo the kind of modulatory changes of NMDAR function reported in this paper. It can be speculated that the nicotine-induced neuro-adaptation of NMDARs present on NAc DA terminals could represent a drug-induced impairment in the glutamatergic control of DA release, which may play a role in the mechanism of nicotine addiction. In this respect, the finding that varenicline pre-treatment was unable to produce any effect on NMDAR function is of interest since this drug has been recently introduced for smoking cessation.
The present results may also be relevant to understand the interplay between nAChR and NMDAR in neurodegenerative diseases. Thus, the activation of NR2B-containing NMDARs, M A N U S C R I P T
19 at either synaptic or extrasynaptic sites, leads to excitotoxicity, whereas activation of NR2A-containing NMDARs promotes neuronal survival and is neuroprotective (Liu et al., 2007) . In contrast, nicotine is suggested to afford neuroprotection, a concept that emerged from several studies documenting an inverse association between cigarette smoking and Parkinson's disease (Ritz et al., 2007) . Nicotine-associated neuroprotection may be linked to the control of NMDARs since the stimulation of α7-containing nAChRs decreased glutamate neurotoxicity through a down regulation of NMDARs and donepezil, an cholinesterase inhibitor, exerts neuroprotective effects via the nicotinic receptor-mediated cascade (Takada et al., 2003) possibly by reducing surface NMDARs and consequently glutamate mediated calcium entry . This is notable agreement with our finding that nicotine pretreatment decreased the function of the NMDARs by reducing the NR2B-containing
NMDARs.
In conclusion, the present results demonstrate, with combined functional and immunocytochemical evidence, the co-localization and functional interaction of nAChRs and NMDARs in NAc dopaminergic terminals. Our results also show that the NMDAR function can be dynamically negatively regulated in neurons in response to a brief activation of nAChRs present on the same nerve endings. This dynamic control of NMDA and also of AMPA receptors (Grilli et al., 2012) 
